MS on DRL OW, TP Rs 5859 - 08.06.2021
Has twin growth engines over next couple of yrs
1) high-value US launches including gKuvan, gVascepa & gRevlimid
2) EM/EU markets along with continued productivity gains
Sputnik V can provide tailwind to earnings
